(Total Views: 457)
Posted On: 05/01/2025 5:09:48 PM
Post# of 154646
Re: biloxiblues #152144
I will give a Cheat sheet
mTNBC Survival & Treatment Cheat Sheet
???? What is mTNBC?
Triple-negative breast cancer that has spread (metastatic)
Lacks estrogen, progesterone, HER2 receptors → few targeted treatments
Fast-growing, hard to treat, especially after first-line therapy fails
???? Median Overall Survival (mOS) benchmarks
1st-line (chemo ± immunotherapy) → 12–17 months
2nd-line (chemo, ADCs like Trodelvy) → 6–9 months
3rd-line+ (mostly chemo) → ~6–6.5 months
???? Approved Late-Line Treatments
Treatment mOS Improvement Notes
Trodelvy (sacituzumab govitecan) ~12 months vs. ~6.7 (chemo) Late-line game-changer, ADC technology
Pembrolizumab + chemo (PD-L1+) ~23 months vs. ~16 (chemo) Only works if PD-L1 positive, 1st line
Atezolizumab + nab-paclitaxel ~25 months (PD-L1+ 1st line) Withdrawn in U.S., confirmatory failure
⚡ Leronlimab (Investigational, CytoDyn)
Small late-line trial → 4 of 28 patients alive after ~36 months
Chemo-refractory, very advanced patients
Survival durability far exceeds expected median (~6 months)
Mechanism: CCR5 blockade → may inhibit tumor metastasis, immune evasion
???? Other Promising Agents (early stage)
Datopotamab deruxtecan (Dato-DXd) → ADC, promising early data
Enfortumab vedotin → ADC, in exploration
Ipatasertib (AKT inhibitor) → mixed results, still under study
CAR-T, bispecific antibodies → very early, experimental
???? Why is leronlimab exciting?
Potential for paradigm-shifting late-line survival
Unique immune and anti-metastatic mechanism
Needs larger confirmatory trials to validate small-study signals
???? Takeaway
If leronlimab’s durability holds up, it could join or exceed Trodelvy’s impact in mTNBC, providing hope in one of the toughest-to-treat cancers.
mTNBC Survival & Treatment Cheat Sheet
???? What is mTNBC?
Triple-negative breast cancer that has spread (metastatic)
Lacks estrogen, progesterone, HER2 receptors → few targeted treatments
Fast-growing, hard to treat, especially after first-line therapy fails
???? Median Overall Survival (mOS) benchmarks
1st-line (chemo ± immunotherapy) → 12–17 months
2nd-line (chemo, ADCs like Trodelvy) → 6–9 months
3rd-line+ (mostly chemo) → ~6–6.5 months
???? Approved Late-Line Treatments
Treatment mOS Improvement Notes
Trodelvy (sacituzumab govitecan) ~12 months vs. ~6.7 (chemo) Late-line game-changer, ADC technology
Pembrolizumab + chemo (PD-L1+) ~23 months vs. ~16 (chemo) Only works if PD-L1 positive, 1st line
Atezolizumab + nab-paclitaxel ~25 months (PD-L1+ 1st line) Withdrawn in U.S., confirmatory failure
⚡ Leronlimab (Investigational, CytoDyn)
Small late-line trial → 4 of 28 patients alive after ~36 months
Chemo-refractory, very advanced patients
Survival durability far exceeds expected median (~6 months)
Mechanism: CCR5 blockade → may inhibit tumor metastasis, immune evasion
???? Other Promising Agents (early stage)
Datopotamab deruxtecan (Dato-DXd) → ADC, promising early data
Enfortumab vedotin → ADC, in exploration
Ipatasertib (AKT inhibitor) → mixed results, still under study
CAR-T, bispecific antibodies → very early, experimental
???? Why is leronlimab exciting?
Potential for paradigm-shifting late-line survival
Unique immune and anti-metastatic mechanism
Needs larger confirmatory trials to validate small-study signals
???? Takeaway
If leronlimab’s durability holds up, it could join or exceed Trodelvy’s impact in mTNBC, providing hope in one of the toughest-to-treat cancers.
(7)
(0)
